Dianthus Therapeutics, INC /DE/ Schedule 13G passive stakes
NASDAQ
SCHEDULE 13G/A: Octagon Capital Advisors and Affiliates Report Significant Stake in Dianthus Therapeutics
Octagon Capital Advisors LP, along with its affiliated funds and managing member Ting Jia, has reported a collective beneficial ownership of 7.1% in Dianthus Therapeutics, Inc. common stock as of December 31, 2024.